Esomeprazole magnesium trihydrate CAS 217087-09-7

Introduction：Basic information about Esomeprazole magnesium trihydrate CAS 217087-09-7, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Esomeprazole magnesium trihydrate Basic information

• Product Name: Esomeprazole magnesium trihydrate
• Synonyms: ESOMEPRAZOLE MAGNESIUM TRIHYDRATE;bis(5-methoxy-2-[(s)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1h-benzylimidazole-1-yl) magnesium trihydrate;(T-4)-Bis[5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazolato]magnesium;Nexium;ESOPMEPRAZOLE MG TRIHYDRATE;5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]benzimidazol-1-ide;5-methoxy-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]benzimidazol-1-ide;5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide
• CAS: 217087-09-7
• MF: C34H38MgN6O7S2
• MW: 731.14
• EINECS: 669-839-3
• Product Categories: Acid pump inhibitors;Chiral Reagents;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 217087-09-7.mol

Esomeprazole magnesium trihydrate Chemical Properties

• Melting point: 184-189°C (dec.)
• storage temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• solubility: Slightly soluble in water, soluble in methanol, practically insoluble in heptane.
• form: Solid
• color: White to off-white
• Major Application: pharmaceutical (small molecule)
• InChI: InChI=1S/2C17H18N3O3S.Mg.H2O/c2*1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;;/h2*5-8H,9H2,1-4H3;;1H2/q2*-1;+2;
• InChIKey: VEVZQDGATGBLIC-UHFFFAOYSA-N
• SMILES: C(C1N=CC(C)=C(OC)C=1C)S1C2[N-]C3=CC(OC)=CC=C3N=2[Mg+2]2(O=S(CC3N=CC(C)=C(OC)C=3C)C3[N-]C4=CC(OC)=CC=C4N2=3)O=1.O
• CAS DataBase Reference: 217087-09-7(CAS DataBase Reference)

Safety Information

• Hazard Codes: Xn
• Risk Statements: 22
• WGK Germany: 3
• HS Code: 2933399090
• Storage Class: 11 - Combustible Solids

Esomeprazole magnesium trihydrate Usage And Synthesis

Chemical Properties

Off-White Powder

Uses

S-Form of Omeprazole. Gastric proton-pump inhibitor

Uses

esomeprazole magnesium trihydrate for the healing of peptic ulcers associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy.

1. Zollinger-Ellison syndrome
2. Peptic ulcer, site unspecified
3. Duodenal ulcer
4. Gastric ulcer
5. Gastro-oesophageal reflux disease

Esomeprazole belongs to the family of medications known as proton pump inhibitors (PPIs). Esomeprazole is registered by the Therapeutic Goods Administration (TGA) for the following indications:

1. Gastro-Oesophageal Reflux Disease (GORD):
2. treatment of erosive reflux oesophagitis;
3. long-term management of patients with healed oesophagitis to prevent relapse;
4. symptomatic treatment of gastro-oesophageal reflux disease (GORD).

In combination with appropriate antibiotics for:

1. healing of duodenal ulcer associated with Helicobacter pylori;
2. eradication of Helicobacter pylori in patients with active or healed peptic ulcer.
3. Short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug (NSAID) (non-selective and COX-2 selective) therapy.
4. Healing of gastric ulcers associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy.
5. Prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy in patients at risk.

Uses

Esomeprazole Magnesium Trihydrate is used in preparation of esomeprazole magnesium trihydrate.

Brand name

Nexium (AstraZeneca).

Biological Activity

Esomeprazole magnesium trihydrate ((S)-Omeprazole magnesium trihydrate) is a potent, orally active H+, K+-ATPase inhibitor. Esomeprazole magnesium trihydrate has the potential for upper intestinal disorders and gastroesophageal reflux disease research. Esomeprazole magnesium trihydrate acts as an exosome inhibitor by blocking the exosome release by inhibiting V-H+-ATPases.

in vivo

Esomeprazole magnesium (0.5-50 mg/kg; oral gavage; daily; for 10 days; A/J mice) treatment increases gastric total antioxidant capacity and Cu/Zn-superoxide dismutase activity^[1].

• Animal Model: A/J mice^[1]
• Dosage: 0.5 mg/kg, 5 mg/kg, 50 mg/kg
• Administration: Oral gavage; daily; for 10 days
• Result: Gastric total antioxidant capacity and Cu/Zn-superoxide dismutase activity are increased.